<DOC>
	<DOCNO>NCT00336713</DOCNO>
	<brief_summary>The purpose study evaluate long-term efficacy safety Saredutant patient depression . The primary objective evaluate efficacy safety Saredutant 100 mg daily compare placebo prevention relapse depressive symptom outpatient major depressive disorder achieve initial response 12 week open-label treatment Saredutant .</brief_summary>
	<brief_title>A 24-52-week Study Evaluate Long-term Efficacy Safety Saredutant Patients With Depression ( MAGENTA )</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<criteria>Diagnosis major depressive disorder , define Diagnostic Statistical Manual Mental Disorders 4th edition ( DSMIV ) criterion confirm semistructured Mini International Neuropsychiatric Interview ( MINI ) , recurrent episode . Total score 28 less Montgomery Asberg Depression Rating Scale ( MADRS ) . Clinical Global Impression ( CGI ) severity score less 4 . Duration current depressive episode less 2 month great 2 year . Elderly patient MiniMental State Examination ( MMSE ) total score &lt; 25 . Patients history presence bipolar disorder psychotic disorder . Patients alcohol dependence abuse substance dependence abuse past 12 month except nicotine caffeine dependence . Benzodiazepine sedativehypnotic use great 2 day per week month prior entry Acute Phase . Patients use follow prior entry Acute Phase : antipsychotic within 3 month , fluoxetine within 1 month , Monoamine oxidase inhibitor ( MAOIs ) within 2 week , antidepressant moodstabilizer ( lithium , anticonvulsant ) within 1 week . The investigator evaluate whether reason patient may participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>antidepressive agent</keyword>
	<keyword>control clinical trial</keyword>
</DOC>